

Revised forms for the submission of the Confidence-Building Measures

At the Third Review Conference it was agreed that all States Parties present the following declaration, later amended by the Seventh Review Conference:

Declaration form on Nothing to Declare or Nothing New to Declare for use in the information exchange

Measure	Nothing to declare	Nothing new to declare	Year of last declaration if nothing new to declare
A, part 1	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
B	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

(Please mark the appropriate box(es) for each measure with a tick, and fill in the year of last declaration in the last column where applicable.)

Date: April 15, 2013

State Party to the Convention: JAPAN

Date of ratification/accession to the Convention: June 8, 1982

National point of contact: Naomi Takahashi, Ministry of Foreign affairs of Japan

Confidence-Building Measure "A"

Part 1 Exchange of data on research centres and laboratories

<1>

Exchange of data on research centres and laboratories

1. Name(s) of facility RIKEN Tsukuba Institute
2. Responsible public or private organization or company The Institute of Physical and Chemical Research (RIKEN)
3. Location and postal address 3-1-1,Koyadai,Tsukuba-shi,Ibaraki,305-0074,JAPAN
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
Ministry of Education,Culture,Sports,Science and Technology
5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)
2 units,82 m²×2
6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate
Risk assessment of recombinant DNA materials using Retrovirus.

<2>

Exchange of data on research centres and laboratories

1. Name(s) of facility Murayama Annex of National Institute of Infectious Diseases (former National Institute of Health)
2. Responsible public or private organization or company
Ministry of Health, Labour and Welfare
3. Location and postal address
Gakuen4-7-1, Musashimurayama, Tokyo 208-0011 Japan
4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence
Ministry of Health, Labour and Welfare
5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)
Three P4 Laboratories, Seventeen P3 Laboratories and their supporting Laboratories (2,270.36 m² in totals).
6. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate
Laboratory diagnosis of viral haemorrhagic fever such as Lassa, Marburg and Ebola diseases. (However, such diagnosis has never been performed in these laboratories so far).

Part 2 Exchange of information on national biological defence research and development programmes

Form A, part 2 (i)

**National biological defence research and development programmes
Declaration**

Are there any national programmes to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such programmes would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes/No

Technical Research & Development Institute (TRDI), Ministry of Defense, Japan (MOD) has conducted research on detection of biological agents.

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of each programme.

Form A, part 2 (ii)

National biological defence research and development programmes

<1>

Description

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Program conducted in JFY 2012 by Technical Research & Development Institute, Ministry of Defense, Japan (MOD) was Research on Detection of Biological Agents.

2. State the total funding for each programme and its source.

Approximately 366 million Japanese yen for Research on Detection of Biological Agents. It is sponsored by Ministry of Defense, Japan (MOD).

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

Yes/No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

56%


5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

The objectives and research areas of the program for JFY 2012 were as follows:

(1) Research on Detection of Biological Agents was primarily performed by Japan Steel Works, LTD.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).

Research on Detection of Biological Agents



<2>

1. State the objectives and funding of each programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

The Japan Ground Self-Defense Force's biological defence research and development programmes for FY2012 include:

Research of molecular biological diagnosis for biological agent casualties

Research of aerobiology

2. State the total funding for each programme and its source.

Approximately 3,253,000 Japanese yen, founded by the Ministry of Defense

3. Are aspects of these programmes conducted under contract with industry, academic institutions, or in other non-defence facilities?

~~Yes~~/No

4. If yes, what proportion of the total funds for each programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of each programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of each programme and the reporting relationships (include individual facilities participating in the programme).

7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to each national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

Form A, part 2 (iii)

National biological defence research and development programmes

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

Military Medicine Research Unit, Test & Evaluation Command, Japan Ground Self-Defense Force

2. Where is it located (include both address and geographical location)?

1-2-24, Ikejiri Setagaya-ku, Tokyo 154-0001, Japan

3. Floor area of laboratory areas by containment level:

BL2 Approximately 42 (sqM)

BL3 0 (sqM)

BL4 0 (sqM)

Total laboratory floor area 104 (sqM)

4. The organizational structure of each facility.

(i) Total number of personnel _____

(ii) Division of personnel:

Military _____

Civilian _____

(iii) Division of personnel by category:

Scientists _____

Engineers _____

Technicians _____

Administrative and support staff _____

(iv) List the scientific disciplines represented in the scientific/engineering staff.

Ph.D. of Medicine

(v) Are contractor staff working in the facility? If so, provide an approximate number.

No

(vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

The Ministry of Defense (wholly)

(vii) What are the funding levels for the following programme areas:

Research cannot be divided into each area

Development cannot be divided into each area

Test and evaluation cannot be divided into each area

(viii) Briefly describe the publication policy of the facility:

No official policy. Individually authorized by the MOD

(ix) Provide a list of publicly-available papers and reports resulting from the work published during the previous 12 months. (To include authors, titles and full references.)

None

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms and/or toxins studied, as well as outdoor studies of biological aerosols.

Research and Development of medical diagnosis/treatment and prevent medicine for casualties in action.

Confidence-Building Measure "C"

Encouragement of publication of results and promotion of use of knowledge

The Government of Japan maintains an open policy on the exchange of information on biological research, the results of such research being made freely available in all cases where the release is not prejudicial to vital national or commercial interests. This policy would be apply to any research subject to the reporting in Forms A and B.

Relevant information of National Institute of Infectious Disease (NIID) is available at the following site.

1) Lists of scientific papers in English and Japanese, which are published by the staffs of National Institute of Infectious Disease (NIID), can be seen in the web site of NIID.

<http://www.nih.go.jp/niid/en/>

2) NIID publishes bimonthly Japanese Journal of Infectious Diseases (JJID), the leading infectious disease journal in Japan. JJID receives more than 250 manuscripts per year from authors around the world. It has been donated to more than 75 countries. JJID is available at the journal site.

<http://www.nih.go.jp/niid/en/>

A selected article published in the journal :

Kazuo Ohnishi, Yoshimasa Takahashi, Naoko Kono, Noriko Nakajima, Fuminori Mizukoshi, Shuhei Misawa, Takuya Yamamoto, Yu-ya Mitsuki, Shu-ichi Fu, Nakami Hirayama, Masamichi Ohshima, Manabu Ato, Tsutomu Kageyama, Takato Odagiri, Masato Tashiro, Kazuo Kobayashi, Shigeyuki Itamura, and Yasuko Tsunetsugu-Yokota: Newly Established Monoclonal Antibodies for Immunological Detection of H5N1 Influenza Virus. JJID 65: 19-27,2012

Gaowa, Wuritu, Dongxing Wu, Yuko Yoshikawa, Norio Ohashi, Fumihiko Kawamori, Kanji Sugiyama, Masayoshi Ohtake, Masataka Ohashi, Seigo Yamamoto, Tomokazu Kitano, Nobuhiro Takada, and Hiroki Kawabata: Detection and Characterization of *p44/msp2* Transcript Variants of *Anaplasma phagocytophilum* from Naturally Infected Ticks and Wild Deer in Japan. JJID 65: 79-83, 2012

Shigeo Iki, Itsuko Horiguchi, Mika Shigematsu, Tetsutaro Sata, Kazuyoshi Sugiyama: Qualitative Analysis of the Perception and Acceptability of Pathogen Transport among Housewives Using Focus Group Interviews. JJID 65: 403-409, 2012

3) Publications in other journals

Kuroda M, Sekizuka T, Shinya F, Takeuchi F, Kanno T, Sata T, Asano S. Detection of a possible bioterrorism agent, *Francisella* sp., in a clinical specimen by use of next-generation direct DNA sequencing. J Clin Microbiol. ;50(5):1810-2. 2012

Fukushi, S., Nakauchi, M., Mizutani, T., Saijo, M., Kurane, I. and Morikawa, S.: Antigen-capture ELISA for the detection of Rift Valley fever virus nucleoprotein using new monoclonal antibodies. Journal of Virological Methods. 180:68-74, 2012.

Sayama, Y., Demetria, C., Saito, M., Azul, R.R., Taniguchi, S., Fukushi, S., Yoshikawa, T., Iizuka, I., Mizutani, T., Kurane, I., Malbas, F.F. Jr, Lupisan, S., Catbagan, D.P., Animas, S.B., Morales, R.G., Lopez, E.L., Dazo, K.R., Cruz, M.S., Olveda, R., Saijo, M., Oshitani, H., and Morikawa, S.: A seroepidemiologic study of Reston ebolavirus in swine in the Philippines. BMC Veterinary Research. 8: 82-90, 2012.

Fukushi S, Tani H, Yoshikawa T, Saijo M and Morikawa S : Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers. Viruses 4: 2097-2114, 2012

Results of biological research related to the Convention such as the one below are also made freely available to States parties.

N. Muroga, Y. Hayama, T. Yamamoto, A. Kurogi, T. Tsuda, T. Tsutsui. (2012) The 2010 foot-and-mouth disease epidemic in Japan.

J Vet Med Sci. 74(4):399-404. doi: 10.3201/eid1803.110908.

https://www.jstage.jst.go.jp/article/jvms/74/4/74_11-0271/_article

Confidence-Building Measure "E"

Declaration of legislation, regulations and other measures

Form E

Declaration of legislation, regulations and other measures

Relating to	Legislation	Regulations	Other measures	Amended since last year
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(b) Exports of micro-organisms and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(c) Imports of micro-organisms and toxins	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No
(d) Biosafety and biosecurity	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	<input type="checkbox"/> Yes/ <input type="checkbox"/> No	Yes/ <input type="checkbox"/> No

Name of legislation, regulations and other measures;

Foreign exchange and Foreign Trade Law (1948)

Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction and the Other Conventions (1982)

Cabinet Order for the Enforcement of the Law on Implementing the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction (1995)

The Law Concerning the Prevention of Infections and Medical Care for Patients of Infections (1998)

Confidence-Building Measure "F"

Form F

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State Party.

June 8, 1982

2. Past offensive biological research and development programmes:

None

3. Past defensive biological research and development programmes:

None

Confidence-Building Measure "G"

Form G

Declaration of vaccine production facilities (UPDATED, March 2013)

No.	Name of Facility	Location (postal address)	General Description of the Types of Diseases Covered
1	Denka Seiken Co., Ltd	2-1-1 Nihonbashi Muromachi, Chuo-ku, Tokyo, Japan	Influenza, Tetanus
2	Kitasato Daiichi Sankyo Vaccine Co.,Ltd	6-111 Arai, Kitamoto-shi, Saitama, Japan	Influenza, Rubella, Diphtheria, Tetanus, Pertussis, Measles, Mumps
3	Takeda Pharmaceutical Co.,Ltd	4-1-1 Doshomachi, Chuo-ku, Osaka, Japan	Diphtheria, Tetanus, Pertussis, Measles, Mumps, Rubella
4	The Research Foundation for Microbial Diseases of Osaka University (BIKEN)	3-1 Yamadaoka, Suita-shi, Osaka, Japan	Influenza, Diphtheria, Tetanus, Varicella, Japanese Encephalitis, Pertussis, Measles, Rubella, Poliomyelitis
5	The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)	1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto, Japan	Influenza, Rabies, Diphtheria, Tetanus, Japanese Encephalitis, Pertussis, Mumps, Hepatitis A, Hepatitis B, Poliomyelitis
6	Japan BCG Laboratory	4-2-6 Kohinata, Bunkyo-ku, Tokyo, Japan	Tuberculosis
7	Japan Poliomyelitis Research Institute	5-34-4 Kumegawa-cho, Higashimurayama-shi, Tokyo, Japan	Poliomyelitis